Anatomical and functional organization of cardiac fibers in the porcine cervical vagus nerve allows spatially selective efferent neuromodulation

Nicole Thompson,Enrico Ravagli,Svetlana Mastitskaya,Ronald Challita,Joseph Hadaya,Francesco Iacoviello,Ahmad Shah Idil,Paul R. Shearing,Olujimi A. Ajijola,Jeffrey L. Ardell,Kalyanam Shivkumar,David Holder,Kirill Aristovich
DOI: https://doi.org/10.1101/2024.01.09.574861
2024-03-04
Abstract:Cardiac disease progression reflects the dynamic interaction between adversely remodeled neurohumoral control systems and an abnormal cardiac substrate. Vagal nerve stimulation (VNS) is an attractive neuromodulatory option to dampen this dynamic interaction; however, it is limited by off-target effects. Spatially-selective VNS (sVNS) offers a promising solution to induce cardioprotection while mitigating off-target effects by specifically targeting pre-ganglionic parasympathetic efferent cardiac fibers. This approach also has the potential to enhance therapeutic outcomes by eliminating time-consuming titration required for optimal VNS. Recent studies have demonstrated the independent modulation of breathing rate, heart rate, and laryngeal contraction through sVNS. However, the spatial organization of afferent and efferent cardiac-related fibers within the vagus nerve remains unexplored. By using trial-and-error sVNS in combination with micro-computed tomography fascicle tracing, we show the significant spatial separation of cardiac afferent and efferent fibers (179±55° SD microCT, p<0.05 and 200±137° SD, p<0.05 sVNS – degrees of separation across a cross-section of nerve) at the mid-cervical level. We also show that cardiac afferent fibers are located in proximity to pulmonary fibers consistent with recent findings of cardiopulmonary convergent neurons and circuits. We demonstrate the ability of sVNS to selectively elicit desired scalable heart rate decrease without stimulating afferent-related reflexes. By elucidating the spatial organization of cardiac-related fibers within the vagus nerve, our findings pave the way for more targeted neuromodulation, thereby reducing off-target effects and eliminating the need for titration. This, in turn, will enhance the precision and efficacy of VNS therapy in treating cardiac pathology, allowing for improved therapeutic efficacy.
Neuroscience
What problem does this paper attempt to address?
This paper aims to solve the problems existing in the existing vagus nerve stimulation (VNS) technology in the treatment of heart diseases. Specifically, there are two main problems in the current VNS technology when treating heart diseases: 1. **Non - selective stimulation**: Current VNS methods usually stimulate the entire vagus nerve and lack the ability of spatial selectivity, resulting in the indiscriminate activation of non - target effectors and thus producing unnecessary side effects. These side effects are mainly caused by the activation of afferent fibers, such as coughing and gastrointestinal discomfort. 2. **Requiring long - time adjustment**: Due to the above non - target effects, the treatment effect of VNS needs about 4 weeks to be adjusted to the optimal level, which is a major problem for the rapidly progressive adverse dynamic remodeling after myocardial infarction. The time delay may lead to irreversible damage to the heart and nerve tissues. To overcome these problems, this study proposes a spatially - selective vagus nerve stimulation (sVNS) method. Through this method, the efferent heart - related fibers can be specifically activated while avoiding the activation of afferent fibers, thereby reducing side effects and shortening the time required to achieve the treatment effect. The specific objectives of the study include: 1. **Exploring the spatial separation and organization of cardiac afferent and efferent fibers**: To study whether there is a spatial separation and organization of cardiac afferent and efferent fibers in the middle section of the right vagus nerve in the pig's neck. 2. **Verifying the feasibility of sVNS**: To study whether sVNS can specifically activate the cardiac efferent fibers without activating the afferent fibers, thereby improving the treatment effect of heart diseases, reducing side effects, and eliminating the need for dose adjustment. Through the achievement of these objectives, the study aims to pave the way for more precise and effective VNS therapies, especially in the treatment of myocardial infarction and other heart diseases.